Gould & Ratner, with Fred Tannenbaum as lead partner, and with the help of Ammara Khan and Julie Gracz, recently represented our client, EternaTear, developer of a next-generation, over-the-counter (OTC), preservative-free artificial tear for dry eye sufferers, announced today it has completed its oversubscribed Series A round of financing. EternaTear is developing a novel artificial tear formulation designed to supplement all layers of the eye’s tear film, thereby providing relief from dry eye more effectively than currently marketed products. The funding will be used by EternaTear to take its product to be ready for market launch, including completion of a multi-site clinical marketing study and U.S. Federal Drug Administration OTC registration.
In August, EternaTear’s CEO, Tim Willis, participated in our Barracuda Boardroom event. As a result of that additional publicity was able to attain more of the investors and funding needed.